RIO DE JANEIRO, BRAZIL - The vaccine against Covid-19 developed by Moderna in partnership with NIH has an overall efficacy of 94.1%, according to a study published on Wednesday, December 30th, in the New England Journal of Medicine. The preliminary data analysis of phase 3 trial found that the immunizer is able to protect against severe cases of the disease.
The efficacy results are based on the data analysis of 30,420 volunteers in the United States. Of these, 15,210 were administered the vaccine and the other half a placebo. The vaccine was administered in two doses, in . . .